Neoadjuvant immunotherapy is safe before surgery in head and neck squamous cell carcinoma. Is it time to challenge the standard-of-care?

Cancer. 2024 Mar 15;130(6):846-847. doi: 10.1002/cncr.35198. Epub 2024 Jan 18.

Authors

Neil D Gross¹, Tanguy Y Seiwert²

Affiliations

¹ Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.

PMID: 38236709
DOI: 10.1002/cncr.35198

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Squamous Cell* / pathology
Carcinoma, Squamous Cell* / surgery
Head and Neck Neoplasms* / surgery
Humans
Immunotherapy / adverse effects
Neoadjuvant Therapy
Squamous Cell Carcinoma of Head and Neck / surgery